Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 141923
- Development stage
- Unknown
- Lead developer
- Ionis Pharmaceuticals
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous, Intrathecal, Intracerebroventricular, Intravitreal, Intraperitoneal
01
Overview
ISIS 141923 is a synthetic antisense oligonucleotide (ASO) designed as a negative control for preclinical and pharmacological studies. It is a 20-nucleotide phosphorothioate oligonucleotide with full 2'-O-(2-methoxyethyl) (2'-MOE) modifications at the ends and deoxynucleosides in the central region. The sequence of ISIS 141923 does not have perfect complementarity to any known gene in public databases and thus does not target or modulate any specific mRNA. Its primary use is as a "scrambled" or non-targeting control in experiments evaluating the effects of other gene-specific antisense oligonucleotides. Developed by Ionis Pharmaceuticals (formerly Isis Pharmaceuticals), it has been widely used to demonstrate specificity and safety profiles of therapeutic ASOs[1][2][6][7].
- Other names
- Control ASO ISIS 141923control ASOscrambled control ASO
Beyond the preview
Go deeper on ISIS 141923.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 141923.